StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday. Separately ...

CNL, Canada's premier nuclear science facility, will conduct preclinical studies combining alpha-particle radiotherapy Actinium-225 ("Ac-225") with Defence's proprietary Accum ® delivery technology.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.